印度新冠相关毛霉病疫情的多中心病例对照研究
研究在印度25家医院开展2021年1–6月的新冠相关毛霉病(CAM)病例对照研究,纳入1,733例CAM病例和3,911例年龄匹配的新冠对照,发现累积糖皮质激素剂量、锌补充、C反应蛋白升高、肾移植、糖尿病、新冠期间糖尿病酮症酸中毒及农村居住与CAM显著相关,12周死亡率为32.2%(473/1,471)。作者强调合理使用新冠治疗药物并优化血糖控制以预防CAM。
要点
- 累积糖皮质激素剂量(OR 1.006,95%CI 1.004–1.007)和锌补充(OR 2.76,95%CI 2.24–3.40)与CAM显著相关。
- 糖尿病(OR 6.72,95%CI 5.45–8.28)和肾移植(OR 7.58,95%CI 3.31–17.40)与CAM显著相关。
- 12周死亡率为32.2%(473/1,471),作者强调合理使用新冠治疗药物并优化血糖控制。
核心结论
- 不恰当的糖皮质激素治疗和锌补充与新冠相关毛霉病显著相关,作者强调合理使用新冠治疗药物并优化血糖控制以预防CAM。
研究设计与样本
- 研究为在印度25家医院开展的多中心病例对照研究,研究时段为2021年1–6月,纳入1,733例CAM病例和3,911例年龄匹配的新冠对照。
主要发现
- 累积糖皮质激素剂量(OR 1.006,95%CI 1.004–1.007)和锌补充(OR 2.76,95%CI 2.24–3.40)与CAM显著相关。
- C反应蛋白升高(OR 1.004,95%CI 1.002–1.006)与CAM显著相关。
- 肾移植(OR 7.58,95%CI 3.31–17.40)、糖尿病(OR 6.72,95%CI 5.45–8.28)和新冠期间糖尿病酮症酸中毒(OR 4.41,95%CI 2.03–9.60)与CAM显著相关。
- 农村居住(OR 2.88,95%CI 2.12–3.79)与CAM显著相关。
- 12周死亡率为32.2%(473/1,471)。
临床怎么用
- 作者强调合理使用新冠治疗药物并优化血糖控制以预防CAM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM. We found inappropriate glucocorticoid therapy and zinc supplementation were significantly associated with these illnesses.
引用
- Muthu V, Agarwal R, Rudramurthy SM, et al. Multicenter Case-Control Study of COVID-19-Associated Mucormycosis Outbreak, India. Emerg Infect Dis. 2023. PMID: 36573628. doi:10.3201/eid2901.220926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。